NCT05866029

Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

Efficacy of Sequential Denosumab After Teriparatide for 6 Months Compared With Denosumab Monotherapy in Reducing Risk of Osteoporotic Fractures in Patients With New Fractures: a Multicenter Randomized Controlled Trial (STAND Study)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 2,478 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 45 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This project anchors osteoporotic fractures, conduct registration and follow-up studies, and conduct prospective treatment studies. By registering for follow-up studies on osteoporotic fractures, it is planned to obtain epidemiological data through registration and follow-up studies; A prospective treatment study for patients with osteoporotic fractures is planned to explore effective treatment strategies through randomized controlled trials; To study biomarkers for osteoporotic refractures, we plan to establish a biomarker warning model through multi omics research; To study imaging biomarkers for osteoporotic refractures, a new imaging technology is proposed to establish an imaging omics warning model.

Conditions

• Osteoporotic Fractures

Interventions

Type	Name	Description
DRUG	Denosumab	Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
DRUG	Teriparatide	Teriparatide was sequentially treated with Denosumab

Timeline

• Start date: 2023-05-26
• Primary completion: 2026-09-30
• Completion: 2026-09-30
• First posted: 2023-05-19
• Last updated: 2026-01-12

Locations

58 sites across 1 country: China